文献速递脊柱关节炎

肿瘤坏死因子抑制剂与非甾体抗炎药治疗对早期强直性脊柱炎放射学进展的影响:与治疗期间炎症控制的关系

Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment.
PubMed 文献 · Arthritis Rheumatol · 2018-11-12

纳入215例早期强直性脊柱炎患者(病程<10年),TNFi组135例、NSAID对照组80例,随访4年。TNFi组时间平均CRP低于对照组(0.27±0.30 mg/dl vs 0.61±0.68 mg/dl,P<0.001);校正年龄、吸烟、基线CRP和基线韧带骨赘后,TNFi组2年间mSASSS变化较小(β=-0.90,95%CI -1.51,-0.29),但进一步纳入时间平均CRP后该差异减小(β=-0.52,95%CI -1.17,0.14)。结论认为TNFi有效抑制炎症可减少早期AS放射学进展。

要点

  • TNFi组时间平均CRP低于NSAID对照组(0.27±0.30 mg/dl vs 0.61±0.68 mg/dl,P<0.001)。
  • 校正混杂因素后TNFi组2年mSASSS变化较小(β=-0.90,95%CI -1.51,-0.29)。
  • 进一步校正时间平均CRP后组间差异减小(β=-0.52,95%CI -1.17,0.14)。

核心结论

  • TNFi治疗有效抑制炎症可减少早期强直性脊柱炎的放射学进展。

研究设计与样本

  • 纳入215例早期强直性脊柱炎患者(症状持续时间<10年),TNFi组135例、NSAID对照组80例。
  • 由两名盲法阅片者采用改良Stoke强直性脊柱炎脊柱评分(mSASSS)评估放射学进展。
  • 炎症控制以两次放射学评估之间时间平均的C反应蛋白(CRP)水平推断。
  • 采用线性混合模型估计放射学间隔内mSASSS变化及临床因素对结局的影响。

主要发现

  • TNFi组较对照组病程更长、基线CRP水平更高、Bath强直性脊柱炎疾病活动指数更高。
  • 放射学间隔内时间平均CRP水平TNFi组低于NSAID组(均值±标准差0.27±0.30 mg/dl vs 0.61±0.68 mg/dl;P<0.001)。
  • 总体2年间隔内mSASSS变化均值±标准差为1.30±2.97单位。
  • 校正年龄、吸烟状态、基线CRP水平及基线韧带骨赘后,TNFi组2年间隔内mSASSS变化较小(β=-0.90[95%CI -1.51,-0.29])。
  • 额外纳入时间平均CRP水平后,其显著影响mSASSS变化(β=1.02[95%CI 0.32,1.71]),组间估计差异减小(β=-0.52[95%CI -1.17,0.14])。

关键数值与推荐

  • 早期强直性脊柱炎定义为症状持续时间<10年。
  • 放射学进展采用mSASSS评估。
  • 炎症控制以放射学间隔内时间平均CRP水平推断。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of tumor necrosis factor inhibitor (TNFi) treatment and inflammation control on radiographic progression in early ankylosing spondylitis (AS) over 4 years. METHODS: We included a total of 215 patients with early AS (symptom duration <10 years) treated with TNFi (the TNFi group; n = 135) or with nonsteroidal antiinflammatory drugs (NSAIDs) (the control group; n = 80). Two blinded readers assessed radiographic progression using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Inflammation control was inferred from C-reactive protein (CRP) levels time-averaged between 2 radiologic assessments. Linear mixed modeling was used to estimate mSASSS changes over radiographic intervals as well as the impact of clinical factors on outcomes. RESULTS: The TNFi group had longer disease duration, a higher baseline CRP level, and a higher Bath Ankylosing Spondylitis Disease Activity Index than did controls. The time-averaged CRP level over radiographic intervals was lower with TNFi treatment than with NSAID treatment (mean ± SD 0.27 ± 0.30 mg/dl versus 0.61 ± 0.68 mg/dl; P < 0.001). Overall, mean ± SD mSASSS change over the 2-year interval was 1.30 ± 2.97 units. In the multivariable model adjusted for age, smoking status, baseline CRP level, and the presence of syndesmophytes at baseline, the TNFi group showed less mSASSS change over the 2-year interval (β = -0.90 [95% confidence interval {95% CI} -1.51, -0.29]). However, when a time-averaged CRP level was additionally included, it significantly influenced the mSASSS change (β = 1.02 [95% CI 0.32, 1.71]), decreasing the estimated group difference (β = -0.52 [95% CI -1.17, 0.14]). NSAID indices of both groups were not associated with either time-averaged CRP levels or mSASSS changes. CONCLUSION: Effective suppression of inflammation by TNFi treatment decreases radiographic progression in early AS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Park JW, Kim MJ, Lee JS, et al. Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment. Arthritis Rheumatol. 2018. PMID: 29984487. doi:10.1002/art.40661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。